Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Evan Vucci / AP
It's looking like President Trump's executive order on drug prices may not have much bite after all.
Kaiser Health News and Politico report that much of the work is being led by Joe Grogan, an Office of Management and Budget official who used to be a lobbyist for Gilead Sciences — the company that helped set off the drug price debate when it charged $1,000 per pill for its hepatitis C drugs. And some of the solutions the task force has discussed are pretty industry-friendly — like giving drugs longer patent protections in foreign markets, a policy that critics say would make them more expensive.
Why it matters: Trump campaigned on populist promises to lower drug prices and has been pushing his team to propose executive actions he can take on his own. These early signs suggest that his executive actions may fall pretty far short of his campaign promises.